Document is current

Article History

Received: 23 August 2024

Accepted: 24 May 2025

First Online: 30 May 2025

Declarations

:

: It is the responsibility of the investigator or qualified designee to obtain signed and dated informed consent for each participant prior to conducting any study-related procedures, following an explanation of the nature of the study—including potential benefits and risks.

: Participants will be informed about how their personal study-related data will be disclosed and will be required to agree to the information contained in the informed consent and provide consent to the processing of their personal data, if required by applicable data protection law. The level of disclosure must also be explained to the participant who will be required to give consent for their data to be used as described in the informed consent.

: MO reports no competing interests. DCC has acted as a consultant for Alexion, AstraZeneca Rare Disease, Wyngaarten Law, and Fitch Law; received travel support from Edwards Lifesciences; and has stock/stock options in Lilly and Edwards. KD has received research funds from NIPRO CORPORATION. AL has consulting agreements with Abbott, Chugai, Renibus Therapeutics, and Alexion AstraZeneca Rare Disease. JLK has received research funds from NIH, Astute-Biomerieux, and Fresenius Medical; and received consulting fees or sat on an advisory board for Alexion, AstraZeneca Rare Disease, Astute-Biomerieux, Baxter, Guard Therapeutics, Novartis, and SeaStar Medical. GL and CMS are employees of Alexion, AstraZeneca Rare Disease. WS and PDW were employees of Alexion, AstraZeneca Rare Disease upon commencing authorship of this manuscript. RLM has consulting agreements with Baxter, AM Pharma, Biomerieux, Mallinckrodt, GE Healthcare, Sanofi, Abiomed, NovaBiomed, Renasym, RenibusTherapeutics, Alexion, AstraZeneca Rare Disease; and has sat on a data and safety monitoring board for Novartis and Guard. PTM is to provide any competing interests. ADS has sat on an advisory board for Alexion AstraZeneca Rare Disease, Novartis, Chugai, RenalGuard, Calcimedica, Retia, AM Pharma, and Fresenius. AZ received consulting fees and grants from DFG, Baxter, Fresenius, Alexion, Bayer, Novartis, AM Pharma, Renibus, Guard Therapeutics, Paion, and Viatris. DTE has sat on advisory boards for Edwards Lifesciences, Astellas Pharma Inc., Medela, and Arthrex Inc. and acted as a consultant for Alexion AstraZeneca Rare Disease, and Renibus Therapeutics.